About KeraLink International

We envision a world free of corneal blindness where cutting-edge, affordable solutions reach every corner of the globe, ensuring no individual is denied the right to sight. By uniting clinicians, technology innovators, governmental and non-governmental organizations, social entrepreneurs, and donors, we aim to make this vision a reality, making comprehensive cornea care accessible and sustainable for all.

The Goal

Helping Where Needed

Having transformed the landscape of corneal treatment in the U.S., KeraLink International has pivoted its expertise globally.

Original U.S. Mission: Complete

KeraLink International helped transform the landscape of corneal treatment by eliminating waiting lists for cornea transplants in the U.S.

Today We Aim To Help LMICs - Starting in India

In India, reports show an estimated 7 million people have corneal blindness in at least one eye. We want to start here.

Proven Success

Our track record speaks volumes to our expertise and effectiveness in the field.

Global Expert Communication

We partner with industry experts & engage top professionals worldwide.

Dedication to Equality

We prioritize inclusivity and equity, ensuring our technologies reach LMICs.

We Envision a World Free of Corneal Blindness

Where cutting-edge, affordable solutions reach every corner of the globe, ensuring that no individual is denied the right to sight. By uniting clinicians, technology innovators, social entrepreneurs, and donors, we aim to turn this vision into a reality, making comprehensive cornea care accessible and sustainable for all.

No one needs to be blind due to corneal disease or injury.

Read Our Mission

Eradicating Corneal Blindness

KeraLink International (KLI) is a 501(c)(3) public charity with a mission to eradicate corneal blindness by providing innovative and affordable solutions and technologies to underserved populations in low- and middle-income countries

Read Our Vision

Our History & Evolution

1962

KLI was founded as the Medical Eye Bank of Maryland.

1980s

KLI became Tissue Banks International and assisted in opening 48 eye banks in 24 countries. KLI became the world’s largest ocular tissue supplier.

1990s

Mission accomplished: KLI helped eliminate waiting lists for cornea transplants in the US, effectively eradicating untreated corneal blindness in the U.S.

2010s

KLI realized that what worked in high-income countries to eradicate corneal blindness would not work in LMICs.

2019

KLI sold its eye banks to focus solely on harnessing the power of new and emerging technologies to eradicate corneal blindness globally in ways not possible before.

2023

KLI launched Pantheon Vision to develop bioengineered corneal implants for use in LMICs and other countries to reduce reliance on human donor tissue.

2023

Today, KLI is the only organization bringing clinicians, technology innovators, healthcare providers, philanthropists, and investors into a coordinated, collaborative effort to eradicate corneal blindness in LMICs.

World Class Stewardship

Michelle Bockman

Chief Executive Officer

Michelle Bockman joined KeraLink International as the CEO with the vision of eradicating corneal blindness in low to mid income countries by developing and investing in current and future proof technologies.

Read Bio

David Green

Chief Technology and Investment Officer

Aaron Chang

Director of Product Development

Donna Smith

Director of Administration

Shelby Tyler

Chief Operating and Financial Officer

KLI’s Distinguished Board: Leaders in Action

Pamela J. Hall

Chairperson, Vice President-Marketing Enovis Corporation

Douglas J. Furlong, Esq.

Vice Chairman; Principal Owner, Furlong ADR, LLC

David Green

Chief Technology Officer, KeraLink International

Sonya Maria Hadrigan, APRN, CIP

Associate Provost, Research Integrity & Compliance Office of the Vice Provost for Research The George Washington University

Mark Jensen, Esq.

Partner, Bowie and Jensen, LLC

Ellen Koo, M.D.

Associate Professor of Clinical Ophthalmology, Bascom Palmer Eye Institute

Roberto Pineda II, M.D.

Director of The Keratorefractive Surgery Service, Massachusetts Eye and Ear Infirmary

C. Thomas Vangsness, Jr., M.D.

Department of Orthopedic Surgery, Professor of Orthopedic Surgery (RET), University of Southern California, Keck School of Medicine, Los Angeles

Fasika Woreta, MD

Director – Ophthalmology Residency Program, Associate Professor of Ophthalmology, Johns Hopkins University

Christopher Helmrath

Founder and Managing Director, SC&H Capital

Joined By Our Global Network – Our extensive network of top-tier specialists are scattered across the globe and equipped with intricate expertise.